NPDUIS Analytical Studies


National Prescription Drug Utilization Information System (NPDUIS) publishes a variety of studies that provide Canadians with comprehensive information on drug pricing, utilization, and cost trends in Canada and internationally. These include Annual Publications, Report Series, Focused Research Reports, and Presentations.

Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20

Insight into the impact of drug shortages in Canada, focusing on the effects on Canadian public drug plans and their beneficiaries.

Find out more…

Meds Pipeline Monitor 2021

This 11th edition features a selection of medicines in Phase III clinical trials or pre-registration in 2021 that have the potential to significantly impact clinical practice and drug spending in Canada.

Find out more…

Meds Entry Watch, 6th Edition

Sixth edition of the PMPRB’s Meds Entry Watch report, which explores the market entry of new medicines in Canada and other countries.

Find out more…

Alignment Among Public Formularies in Canada

Part 3: Medicines Assessed by the Common Drug Review

Find out more…

Annual Publications

CompassRx: Annual Public Drug Plan Expenditure Report

2019/20 Edition
Published: November 2021 | PDF 2.5 MB

Previous Editions

CompassRx,2018/19 
Published: December 2020 | PDF 2.4 MB

CompassRx, 2017/18 
Published: September 2019 | PDF 2.25 MB

CompassRx, 2016/17
Published: September 2018 | PDF 2.80 MB

CompassRx, 2015/16
Published: May 2017 | PDF 2.26 MB

CompassRx, 2013/14
Published: May 2016 | PDF 4.02 MB

CompassRx, 2012/13
Published: March 2015 | PDF 4.37 MB

Analysis Brief: CompassRx, 2012/13
Published: March 2015 | PDF 804 kb


Meds Entry Watch

Meds Entry Watch

6th Edition
Published: April 2022 | PDF 592 KB

Supplementary Information:

New Medicines Approved in 2020 | PDF 101 KB
New Medicines Approved in 2019 | PDF 165 KB
New Medicines Approved in 2018 | PDF 127 KB
New Medicines Approved in 2017 | PDF 97 KB
New Medicines Approved in 2016 | PDF 97 KB

Previous Editions

5th Edition, 2019
Published: February 2021 | PDF 4.7 MB

2018 Edition
Published: January 2020 | PDF 899 KB

2017 Edition
Published: February 2019 | PDF 3.35 MB

2016 Edition
Published: June 2018 | PDF 758 kb

2015 Edition
Published: April 2017 | PDF 2.33 MB


Meds Pipeline Monitor

Meds Pipeline Monitor

2021 Edition
Published: April 2022 | PDF 2.7 MB

Previous Reports

2020 Edition
Published: January 2021 | PDF 4.1 MB

2019 Edition
Published: April 2020 | PDF 2.4 MB

2018 Edition
Published: May 2019 | PDF 1.94 MB

New Drug Pipeline Monitor, 7th Edition
Published: December 2015 | PDF 1.43 MB

New Drug Pipeline Monitor, 6th Edition
Published: December 2014 | PDF 723 kb

New Drug Pipeline Monitor, 5th Edition
Published: December 2013

New Drug Pipeline Monitor, 4th Edition
Published: April 2013

New Drug Pipeline Monitor, 3rd Edition
Published: July 2011

New Drug Pipeline Monitor, 2nd Edition
Published: July 2008

New Drug Pipeline Monitor, 1st Edition
Published: June 2007

Report Series

Formularies in Canada

Formularies in Canada

Part 3: Medicines Assessed by the Common Drug Review
Published: February 2022 | PDF 1.9 MB

Part 2: Oncology Medicines
Published: May 2021 | PDF 2 MB

Part 1: General Overview
Published: October 2017 | PDF 2.07 MB

List of Selected Drugs
Published: October 2017 | PDF 1 MB


Market Intelligence Report

Market Intelligence Report

Combination Inhalers for Asthma, 2018
Published: April 2020 | PDF 4 MB

Previous Reports

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs for Retinal Conditions, 2017
Published: December 2018 | PDF 1 MB

Biologic Response Modifier Agents, 2015 - Supplement: 2017
Published: September 2018 | PDF 875 KB

Biologic Response Modifier Agents, 2015
Published: October 2016 | PDF 2.71 MB


Generics360: Generic Drugs in Canada

Generic360

2018 Edition
Published: August 2019 | PDF 1.10 MB

Previous Reports

Generics360: Generic Drugs in Canada - 2016 Edition
Published: February 2018 | PDF 1.19 MB

Generics360: Generic Drugs in Canada - 2014 Edition
Published: February 2016 | PDF 1.76 MB

Generic Drugs in Canada, 2013
Published: December 2014 | PDF 645 kb

Analysis Brief: Generic Drugs in Canada, 2013
Published: December 2014 | PDF 182 kb

Analytical Snapshot: International Generic Price Comparison, Early 2011
Published: August 2013 | PDF 899 kb

Generic Drugs in Canada: International Price Comparisons and Potential Cost Savings
Published: September 2011 | PDF 368 kb

Generic Drugs in Canada: Market Structure – Trends and Impacts
Published: December 2010 | PDF 310 kb

Generic Drugs in Canada: Price Trends and International Price Comparisons, 2007
Published: December 2010 | PDF 415 kb


Private Drug Plans in Canada

Private Drug Plans in Canada - Part 1: Generic Market 2005–2013

Part 1: Generic Market 2005–2013
Published: December 2015 | PDF 3.02 MB

Focused Reports

Chartbook

Expensive Drugs for Rare Diseases: Canadian Trends and International Comparisons, 2011–2020 
Published: January 2022 | PDF (1.2 MB)

Previous Chartbook

Oncology Medicines in Canada: Trends and International Comparisons, 2010–2019
Published: October 2020 | PDF (1.5 MB)

Biologics in Canada, 2018
Published : May 2020

The market for prescription oral solid opioids, 2010 to 2017
Published: January 2019 | PDF 893 KB

Report

Other NPDUIS Studies

Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20New
Published: September 2022 | PDF 710 KB

Previous Reports

Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13
Published: April 2014 | PDF 3.07 MB

The Drivers of Prescription Drug Expenditures – A Methodological Report
Published: December 2013 | PDF 1.54 MB

The Use of Blood Glucose Test Strips in Select Public Drug Plans, 2008
Published: April 2013 | PDF 666 kb

Wholesale Up-charge Policies of Canada's Public Drug Plans
Published: December 2011/
Revised January 2012 | PDF 260 kb

The Impact of Generic Entry on the Utilization of the Ingredient
Published: September 2011/
Revised May 2012 | PDF 800 kb

Public Drug Plan Dispensing Fees: A Cost-Driver Analysis, 2001/02 to 2007/08
Published: September 2011 | PDF 813 kb

Baby-Boomer Effect on Prescription Expenditures and Claims
Published: December 2010 | PDF 545 kb

Use of the World Health Organization Defined Daily Dose in Canadian Drug Utilization and Cost Analyses
Published: December 2010 | PDF 838 kb

Poster Presentations

Poster Presentations

2022 Posters:

Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20 | PDF 733 KB

The COVID-19 Pipeline: Vaccines and Treatments on the Horizon | PDF 945 KB

Alignment between the estimated therapeutic value of medicines and their Canadian prices | PDF 1 MB

The missing claimants of 2020: Who went without claims in Canada during the first year of the COVID-19 pandemic and what does it mean for public and private insurers? | PDF 1 MB

The COVID-19 Pipeline: Vaccines and Treatments on the Horizon | PDF 379 KB

Insight into approvals, marketing, and pricing of new medicines in Canadian and international markets | PDF 311 KB

The Cost of Drug Shortages for Canadian Insurers | PDF 318 KB

Canada’s Evolving Market for Biosimilars and What It Means for Payers | PDF 507 KB

Previous Posters

2021 Posters:

Playing catch-up: where Canada stands three years into the pCPA–CGPA generics pricing initiative | PDF 383 KB

A pan-Canadian comparison of coverage for hospital and take-home oncology medicines | PDF 429 KB

Changes in Canadian Guidelines for Conducting Budget Impact Analysis | PDF 1.1 MB

2019 Conference Posters:

Biosimilars in Canada: Current Environment and Future Opportunity | PDF 647 KB

Early insight into new medicine launches in Canadian and international markets | PDF 765 KB

Generic Drug Pricing in Canada: Closing the Gap | PDF 685 KB

Uncovering the forces driving costs in Canada’s public drug plans, 2017/18 | PDF 560 KB

The Oncology Drug Market: A High-Growth, High-Price Therapeutic Area | PDF 546 KB

Combination asthma inhalers in Canada: locked on high prices | PDF 497 KB

Alignment of oncology drug coverage across Canada | PDF 1.30 MB

Pressures behind the rising costs in Canadian private drug plans, 2018 | PDF 588 KB

2018 Conference Posters:

The New Drug Landscape: International Availability and Pricing | PDF 375 kb

Generic Drugs in Canada, 2016 | PDF 407 kb

Cost Drivers of Public Drug Plans in Canada, 2016/17 | PDF 406 kb

Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2017 | PDF 556 kb

The Cost of Drugs for Age-related Macular Degeneration in Canada and Internationally | PDF 821 kb

The Cost of New Oral Anti-diabetic Drugs in Canada and Internationally | PDF 2.29 MB

Cost Drivers of Private Drug Plans in Canada, 2017 | PDF 755 kb

2017 Conference Posters:

The Canadian Market for Biologic Response Modifier Agents, 2015 | PDF 305 kb

Generic Drugs in Canada, 2015 | PDF 369 kb

A Review of Public Coverage of CDR Reviewed Drugs | PDF 354 kb

A Review of Public and Private Coverage of iJODR/pCODR Reviewed Drugs | PDF 325 kb

Potential Savings from Biosimilars in Canada | PDF 440 kb

2016 Conference Posters:

Orphan Drug Launch Monitor (ODLM) | PDF 324 kb

Cost Pressures in the Canadian Hospital Drug Market, 2006–2014 | PDF 373 kb

The Use of Diabetes Drugs in Canadian Public Drug Plans | PDF 369 kb

Private Drug Plans in Canada: Cost Drivers, 2008 to 2015 | PDF 400 kb

New Drug Launch Monitor, 2009-2015 | PDF 373 kb

Cost Pressure of the New Hepatitis C Drugs in Canada | PDF 310 kb

Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2015 | PDF 296 kb

2015 Conference Posters:

Generic Drugs in Canada, 2013 | PDF 373 kb

Cost Drivers of Private Drug Plans in Canada, 2012/13 | PDF 400 kb

Cost Drivers of Public Drug Plans in Canada, 2012/13 | PDF 1021 kb

The Use of Gabapentin in Public Drug Plans | PDF 1480 kb

Monitoring New Drugs in Canada: A Multifaceted Approach | PDF 326 kb

Generic Drugs in Canadian Private Plans, 2005–2013 | PDF 338 kb

2014 Conference Posters:

Private Drug Plans in Canada PDF 695 kb

New Drug Pipeline Monitor PDF 378 kb

Slide Presentations

biosimilar

Biosimilars in Canada: building momentum in the wake of recent switching policies
Published: December 2021 | PDF 435 KB

biosimilar

Potential Savings from Biosimilars in Canada
Published: March 2017 | PDF 1.56 MB

Slide Presentations

Tamper-Resistant Properties of Drugs Regulations – Cost Impact Analysis, 2019
Published: September 2015 | PDF 1.23 MB

Resources

Reference Documents

These documents provide background material to supplement the NPDUIS analytical studies:

Canadian Public Drug Plan Designs and Policies

Methods

General Information

Budget Impact Analysis Guidelines

Budget Impact Analysis Guidelines

Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
Published: June 2020 | PDF .87 MB

Date modified: